###### Strengths and limitations of this study

-   Strengths of this study include the importance of unrevealing uncertainty about evidence of using drugs targeting Janus kinase and Signal Transducer and Activator of Transcription proteins pathway when prescribed as *off-label* for dermatological diseases in the clinical setting.

-   We will use an established scoping review methodology, a systematic search developed by two health sciences librarians and systematic screening and data abstraction carried out in duplicate.

-   A limitation of this review is the potential to miss relevant articles, especially in the grey literature. To mitigate this, we will screen meeting abstracts to identify any missed articles describing case reports not published in journals and scan reference lists of included articles and similar reviews.

Introduction {#s1}
============

Improving knowledge of the molecular biology of the cell, and its adaptation to the disease pathogenesis, have allowed the design of new drugs directed against key targets in signalling pathway regulation. In this sense, the Janus kinases (JAKs) and Signal Transducer and Activator of Transcription (STATs) proteins (JAK/STAT) pathway is one of a handful of pleiotropic routes used to transduce multiple extracellular signals involved in cell proliferation, differentiation, migration and apoptosis.[@R1] Alterations in the regulation of this process have been associated with pathological events fundamentally related to immunomodulatory and neoplastic (mainly haematological) disorders. In addition, they have been related to the pathophysiology of several dermatological diseases. Therefore, drugs that act on the JAK/STAT pathway represent an opportunity for the treatment of these disorders.[@R2]

The JAK family is comprised by four types of cytoplasmic tyrosine kinases: JAK1, JAK2, JAK3 and Tyk2.[@R3] STAT, of which there are seven different subtypes (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6), is the other fundamental component of the cascade.[@R4] After being phosphorylated by JAK, STAT translocates to the nucleus to induce the transcription of specific genes. Different types of ligands, from cytokines, such as interleukins (ILs), to hormones, such as erythropoietin, activate this pathway to produce changes in the cell, and eventually in tissue physiology. Some of these molecules have been shown to be important, directly or indirectly, in the development of dermatological diseases. Examples of these are IL-2 and its family, IL-23, interferon alpha[@R5] and IL-17.[@R6] The overall pathway has shown its implication in the pathophysiology of diseases such as psoriasis, atopic dermatitis, lupus erythematous, melanoma or pyoderma gangrenosum.[@R7]

This knowledge has led to the development of drugs that act on the JAK component of the pathway, by selectively inhibiting one (filgotinib, JAK1; pacritinib, JAK2; decernotinib, JAK3) or more than one (tofacitinib, JAK1 and JAK3; ruxolitinib, baricitinib, JAK1 and JAK2) JAK protein.[@R8] Ruxolitinib and tofacinib were the first drugs of this class to be approved by the FDA---in 2011 for myelofibrosis and in 2012 for rheumatoid arthritis, respectively.[@R9]

So far, no JAK/STAT inhibitors have been approved a license for the treatment of dermatological diseases. However, evidence exists resulting from the off-label use of these drugs, specifically tofacitinib and ruxolitinib, in different skin diseases. Knowing the efficacy and safety profile of each drug used in different dermatological diseases is essential to establish their risk--benefit balance.

Improving knowledge requires ordering evidence, establishing gaps in the evidence and formulating questions that can be answered using systematic synthesis and analysis techniques. The aim of this is to develop guidelines that give support to physicians in making effective decisions in clinical practice. For this purpose, secondary scientific studies can develop methodologies that adapt to the specific needs of the formulated problem. The application of JAK inhibitors for the treatment of dermatological disorders is still in its early stages, and we consider it necessary to broadly review the knowledge available to date. Otherwise, the conduction of studies aimed at answering specific questions can lead to synthesis efforts that cannot be quantified.[@R11]

A scope review is a form of scientific synthesis that addresses an exploratory research question, with the aim of mapping key concepts and gaps in research related to a defined area or field.[@R12] The aim of this protocol is to define the methodology that will be used to broadly synthesise the available evidence on the use of inhibitors of the JAK/STAT pathway in dermatological diseases.

Methods {#s2}
=======

Protocol design {#s2a}
---------------

The aim of the study is to broadly address the published evidence on drugs targeting JAK proteins in the treatment dermatological diseases, for three purposes: (a) to structure the existing knowledge in this field; (b) to establish areas where there may be gaps in the evidence; (c) to formulate new questions that can be answered following the methodology of systematic reviews. With this intention, we will use the methodology recently described to conduct scoping reviews.[@R13] This methodology outlines a five-stage approach ([table 1](#T1){ref-type="table"}): (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collate summarise and report the results, with an optional consultation exercise. Finally, we will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews to present the results.[@R14] This protocol is reported following the recommendations of the PRISMA for protocols statement. A checklist for this review protocol has been provided in a [Supplementary file 1](#SP1){ref-type="supplementary-material"}.
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Stages of the scoping reviews

  ------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Research question identified                        1.1. Overarching goal                                                                                                                                                                                                                                                                                To explore the depth and breadth of evidence for the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of patients with dermatological diseases.
                                                          1.2. Research question                                                                                                                                                                                                                                                                               What are the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of dermatological diseases?
                                                          1.3. Purposes of this scoping review                                                                                                                                                                                                                                                                 1.3.1. Review the evidence of indications for drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
                                                                                                                                                                                                                                                                                                                                                               1.3.2. Review the evidence of epidemiology of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
                                                                                                                                                                                                                                                                                                                                                               1.3.3. Review the evidence of genetics of drugs acting on JAK/STAT pathway in the treatment of dermatogical diseases.
                                                                                                                                                                                                                                                                                                                                                               1.3.4. Review the evidence on efficacy of the drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
                                                                                                                                                                                                                                                                                                                                                               1.3.5. Review the evidence on safety of drugs that act on JAK/STAT pathway in the treatment of dermatogical diseases.
                                                                                                                                                                                                                                                                                                                                                               1.3.6. Obtain concrete research questions that can be answered through a systematic review.
                                                                                                                                                                                                                                                                                                                                                               1.3.7. Identify research gaps in the existing literature.
  2\. Identifying relevant literature                     2.1. We will perform a three-step search                                                                                                                                                                                                                                                             2.1.1. First search: an initial limited search of the MEDLINE and EMBASE databases to find keywords in the title, abstract and the index terms used to describe the articles.
                                                                                                                                                                                                                                                                                                                                                               2.1.2. Second search: a search of MEDLINE and EMBASE using all identified keywords. A*dditionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step.*
                                                                                                                                                                                                                                                                                                                                                               2.1.3. Third search: the reference lists of all identified reports and articles will be searched for additional studies.
                                                          2.2. We will include the studies published in full text in English until October 2018.                                                                                                                                                                                                               
                                                          2.3. We will contact authors, of primary studies or reviews, for further information, if this is relevant.                                                                                                                                                                                           
                                                          2.4. The search and selection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.                                                                                                                                                 
  3\. Selecting studies                                   3.1. Inclusion criteria                                                                                                                                                                                                                                                                              3.1.1. We will include in the review the studies on the human use of drugs inhibitors of JAK/STAT pathway published on the topics: indications, epidemiology, genetics, efficacy and safety.
                                                                                                                                                                                                                                                                                                                                                               3.1.2. Design of the studies: we will include guidelines, systematic reviews, randomised clinical trials, observational studies, cross sectional case report and series.
                                                          3.2. Exclusion criteria                                                                                                                                                                                                                                                                              3.2.1. We will exclude narrative reviews and studies performed in vitro or using animal models.
  4\. Charting the data                                   4.1. We will extract the data in a predefined form.                                                                                                                                                                                                                                                  
                                                          4.2. From each study we will extract title, objective, main variables related to patients, intervention, comparator, outcomes (efficacy and safety) and bibliographic data.                                                                                                                          
                                                          4.3. We will classify the studies by treatment indication.                                                                                                                                                                                                                                           
                                                          4.4. The list of studies, variables and data of there view will be published in an online file.                                                                                                                                                                                                      
                                                          4.5. The data collection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.                                                                                                                                                      
  5\. Collating, summarising and reporting results        5.1. The results of comprehensive search will be presented using the PRISMA flow diagram.                                                                                                                                                                                                            
                                                          5.2. We will synthesise qualitatively the evidence obtained ordering it by topics: indications, mechanism of action, efficacy and safety of drugs that act on JAK/STAT pathway to treat dermatological diseases and we will present it in a diagrammatic tabular form and in a descriptive format.   
                                                          5.3. We will use the extension of PRISMA for scoping review for the notification of the review.                                                                                                                                                                                                      
  6\. Differences between the protocol and the overview   Any changes in the methodology that need to be carried out throughout the study will be detailed together with the results publication.                                                                                                                                                              
  ------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

JAK/STAT, Janus kinase and Signal Transducer and Activator of Transcription protein; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Inclusion criteria {#s2b}
------------------

We will use participants, concept, context (PCC) mnemotechnic rule to define the inclusion criteria as follows:

Participants {#s2c}
------------

All studies that include evidence on the use of JAK protein inhibitors in humans will be included. No restrictions regarding age, ethnicity, study design or any other characteristics will be made.

Concept {#s2d}
-------

We will review the existing literature on drugs targeting JAK proteins in the treatment of dermatological diseases: indications, epidemiology, genetics, efficacy and safety.

Context {#s2e}
-------

We will not limit the context to a particular setting or country.

Research question {#s2f}
-----------------

What are the indications, epidemiology, genetics, efficacy and safety of drugs targeting proteins of STAT/JAK pathway for the treatment of dermatological diseases?

Identifying relevant literature {#s2g}
-------------------------------

A systematic search developed by two health sciences librarians will perform using a three-step literature search. The first step will include an initial limited search of the MEDLINE and EMBASE databases ([table 2](#T2){ref-type="table"}). Then, we will carry out analyses of: the text contained in the titles, abstracts of retrieved papers and the index terms used to describe the articles. In second step, we will search the same databases using the identified keywords and index terms. Additionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step. Third, the reference list of all identified reports and articles will be searched for additional studies. We will contact authors of primary studies or reviews for further information, if relevant. We have established a time frame of 4 weeks after sending authors a mail requesting information about their study or publication. We will include all studies published in English until October 2018. The process of searching, extracting key words and filtering and excluding studies, will be carried out independently and by duplicate by at least two researchers and in case of disagreement will be decided by agreement with a third reviewer.

###### 

Draft of first step of search strategy to be used for at least two electronic databases.

  search   
  -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#1      (('tofacitinib\' OR 'baricitinib\' OR 'ruxolitinib\' OR 'oclacitinib\' OR 'upadacitinib\' OR 'delgocitinib\' OR 'itacitinib\' OR 'momelotinib\' OR peficitinib OR 'decernotinib\' OR 'fedratinib\' OR 'pacritinib\' OR 'filgotinib\' OR 'gandotinib\' OR 'solcitinib\' OR 'lestaurtinib\' OR 'janus kinase inhibitor\')
  \#2      (('psoriasis\'/exp OR psoriasis) OR 'atopic dermatitis\' OR 'alopecia\' OR 'contact dermatitis\' OR 'vitiligo\' OR 'graft versus host reaction\' OR 'lichen planus\' OR 'pyoderma gangrenosum\' OR 'pruritus\' OR (eosinofilic AND annulare AND erythema) OR 'male type alopecia\' OR 'proteasome associated autoinflammatory syndrome\' OR 'sting associated vasculopathy with onset in infancy\' OR 'chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome\' OR 'hand dermatitis\' OR 'discoid lupus erythematosus\' OR 'mucocutaneous candidiasis\' OR (urticaria AND chronic) OR 'suppurative hidradenitis\' OR 'melanoma\' OR 'non melanoma skin cancer\' OR 'acne\' OR 'lichen sclerosus et atrophicus\' OR 'pityriasis rubra pilaris\' OR 'pemphigus\' OR 'skin disease\' OR 'rosaceae\' OR 'scleroderma\' OR 'cinca syndrome\' OR 'hyperhidrosis\' OR 'erythropoietic protoporphyria\' OR 'anca associated vasculitis\' OR 'seborrheic dermatitis\' OR 'herpes simplex\' OR 'sjoegren syndrome\'))
  \#3      \#1 AND \#2

Identifying relevant studies {#s2h}
----------------------------

We will apply the inclusion criteria, described previously, for the selection of studies. The process will be carried out by at least two researchers and in case of disagreement will be decided by agreement with a third reviewer.

Charting the data {#s2i}
-----------------

We will develop a draft charting to record the information that will be relevant to the review.

Questions focusing on:*Mapping studies:* author(s), year of publication, origin/country of origin (where the study was published or conducted), authors affiliation, type of study, a priori design, registration, conflict of interest, funding;*Epidemiological and genetics aspects:* study population and sample size, genetic studies;*Evaluation of the efficacy and safety of drugs for each disease*: intervention type, comparator and details of these, duration of the intervention, dosage, outcomes and details of these and adverse events.

The data collection will be done by at least two reviewers using a piloting customised Google AppSheet form (<https://www.appsheet.com/>) and in case of disagreement will be decided by agreement with a third reviewer. We anticipate that we can start retrieving data in April 2019 and finalising by September 2019.

Collating, summarising and reporting results {#s2j}
--------------------------------------------

The elements of the PCC inclusion criteria will guide the presentation of the data. First, we will present the results of the search in the PRISMA flow chart. Second, we will organise the extracted data for topics defined as follows: indications, mechanism of action, efficacy safety and cost. For each category, a clear explanation will be provided. The results of the scoping review will be presented as a map, in both diagrammatic and tabular form, and in a descriptive format. A narrative summary will accompany the tabulated and/or charted results and will describe how the results relate to the review objective and question(s).

Differences between the protocol and the overview {#s2k}
-------------------------------------------------

Changes in the methodology that need to be carried out throughout the study will be detailed in the results section.

Ethics and dissemination {#s2l}
------------------------

This study will analyse only anonymised public data of previously conducted studies, and will not involve any new human or animal studies performed by the authors. We will prepare the publication in accordance with PRISMA guideline and its adaptation for scoping reviews. We will publish our findings in peer-reviewed journals and also may present them at conferences.

Patient and public involvement {#s2m}
------------------------------

Patients and or public were not involved in the development of this protocol. The study group developed this study protocol without patient involvement.

Conclusion {#s3}
==========

Here, we have presented a protocol for systematically conducting a scoping review to broadly analyse the available evidence on the indications for and the mechanisms of action, efficacy and safety of JAK/STAT pathway-targeting drugs in the use of dermatological therapy. Evidence-based medicine is intended to optimise decision making by emphasising the use of evidence derived from well-designed and well-conducted research. Currently, most reviews of treatments blocking the JAK/STAT pathway are narrative reviews, which lack the necessary methodological detail to promote reproducibility and reduce the risk of bias.[@R15] Secondary research methodologies are constantly being developed and must be adapted to the type of research question being asked and the urgency with which the question must be answered.[@R17]

Although we will try to analyse the quality of evidence per variable and disease using Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, probably most of the studies have produced documents communicating partial results following an observational design, which is associated with low or very low quality of evidence. However, we believe that the scoping review methodology is the one of the best suited protocols to answer the question posed in this study. The results will provide unique insights into the available evidence on the use of JAK/STAT pathway-targeting drugs in the treatment of dermatological diseases, facilitating the detection of knowledge gaps and the identification of new questions to address via additional systematic reviews.

Supplementary Material
======================
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